Open AccessAndrogen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)
Author(s) -
Charles J. Ryan,
Sandipan Dutta,
William Kevin Kelly,
Carly Russell,
Eric J. Small,
Michael J. Morris,
MaryEllen Taplin,
Susan Halabi
Publication year - 2019
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-019-0152-3
Subject(s) - medicine , docetaxel , prostate cancer , testosterone (patch) , androgen deprivation therapy , androgen , oncology , urology , endocrinology , placebo , cancer , hormone , pathology , alternative medicine
Multiple androgens drive prostate cancer progression and higher pre-treatment levels of androgens, even within the castrate range, have been previously shown to be associated with an improved overall survival (OS) in mCRPC. Docetaxel impairs microtubules, has androgen receptor (AR) inhibitory effects and is used in both the castration resistant and sensitive settings, where androgen dynamics may impact outcome. The present analysis evaluates the association of decline in serum androgen levels (Testosterone (T), Androstenedione (A) and DHEA in docetaxel-treated mCRPC patients with OS.